Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: a 4-week randomized placebo controlled study

Brain Stimulation
Alan L SchneiderHarry Stark

Abstract

In the absence of effective treatments for the negative symptom complex of schizophrenia, we explored the effect of 4 consecutive weeks of repetitive transcranial magnetic stimulation (rTMS) exposure (20 sessions) as an add-on treatment to atypical antipsychotics. Three groups of 17 schizophrenic subjects each were exposed to 20 treatments of either placebo, 1 Hz (100 pulses per day=2000 total) or 10 Hz (1000 pulses per day=20,000 total) rTMS at 110% motor threshold over the left dorsolateral prefrontal cortex, while being maintained on their atypical antipsychotic. Subjects were evaluated at baseline, weeks 2 and 4, and at 4-week follow-up after the last treatment. The primary outcome measure (change in Scale for Assessment of Negative Symptoms score) showed a statistically significant drop at weeks 2, 4, and 8 for the high frequency (10 Hz) group, but not the 1 Hz or placebo groups. Secondary outcome measures of the Wisconsin Card Sorting Test and SF-36 did not demonstrate any significant change. rTMS may serve as a relatively noninvasive treatment of the negative and neurocognitive deficits associated with schizophrenia.

References

Jul 18, 1992·BMJ : British Medical Journal·J E BrazierL Westlake
Feb 1, 1984·The American Journal of Psychiatry·M A Taylor, R Abrams
Mar 1, 1994·The American Journal of Psychiatry·W S Fenton, T H McGlashan
Oct 1, 1995·Schizophrenia Research·S Dollfus, M Petit
Jan 20, 1998·The American Journal of Psychiatry·E B NelsonS M Strakowski
Aug 5, 1998·International Clinical Psychopharmacology·C A TammingaJ M Gold
Apr 11, 2001·Schizophrenia Research·T L PattersonD V Jeste
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Jul 21, 2004·Psychiatry Research·Andrew M McIntoshKlaus P Ebmeier
May 11, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Paul B FitzgeraldJayashri Kulkarni

❮ Previous
Next ❯

Citations

Sep 18, 2013·Neuropsychologia·Arielle D StanfordSarah H Lisanby
Dec 14, 2011·Neurophysiologie clinique = Clinical neurophysiology·J-P LefaucheurL Garcia-Larrea
Dec 12, 2012·BMC Psychiatry·Cindy L HovingtonMartin Lepage
Aug 10, 2011·Brain Stimulation·Stéphane TringaliAnnie Moulin
Jul 4, 2012·Neuropharmacology·Asli Demirtas-TatlidedeAlvaro Pascual-Leone
Jul 19, 2014·Clinical Neurophysiology : Official Journal of the International Federation of Clinical Neurophysiology·Jean-Pascal LefaucheurLuis Garcia-Larrea
Apr 29, 2011·The International Journal of Neuropsychopharmacology·Yechiel LevkovitzAbraham Zangen
Jun 21, 2016·Expert Review of Clinical Pharmacology·Shyam Sundar ArumughamChittaranjan Andrade
Aug 21, 2015·The Cochrane Database of Systematic Reviews·Nadine DougallAndrew McIntosh
Jan 26, 2017·Experimental Brain Research·Ulf Ziemann
Apr 13, 2021·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Stephen J BrandtMichael M Francis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here